Cellectar Biosciences Inc...

0.28
-0.01 (-4.50%)
At close: Apr 03, 2025, 3:59 PM

Cellectar Biosciences Statistics

Share Statistics

Cellectar Biosciences has 46.08M shares outstanding. The number of shares has increased by 28.54% in one year.

Shares Outstanding 46.08M
Shares Change (YoY) 28.54%
Shares Change (QoQ) 11.66%
Owned by Institutions (%) 0%
Shares Floating 45.31M
Failed to Deliver (FTD) Shares 7.67K
FTD / Avg. Volume 0.46%

Short Selling Information

The latest short interest is 1.84M, so 4.45% of the outstanding shares have been sold short.

Short Interest 1.84M
Short % of Shares Out 4.45%
Short % of Float 4.58%
Short Ratio (days to cover) 8.34

Valuation Ratios

The PE ratio is -0.25 and the forward PE ratio is -0.38. Cellectar Biosciences's PEG ratio is 0.

PE Ratio -0.25
Forward PE -0.38
PS Ratio 0
Forward PS 0.3
PB Ratio 0.77
P/FCF Ratio -0.23
PEG Ratio 0
Financial Ratio History

Enterprise Valuation

Currently the Enterprise Value (EV) is not available for Cellectar Biosciences.

EV / Sales n/a
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF n/a

Financial Position

The company has a current ratio of 2.58, with a Debt / Equity ratio of 0.03.

Current Ratio 2.58
Quick Ratio 2.58
Debt / Equity 0.03
Debt / EBITDA -0.01
Debt / FCF -0.01
Interest Coverage 0

Financial Efficiency

Return on Equity is n/a and Return on Invested Capital is n/a.

Return on Equity n/a
Return on Assets n/a
Return on Invested Capital n/a
Revenue Per Employee $0
Profits Per Employee $-4.05M
Employee Count 11
Asset Turnover 0
Inventory Turnover n/a

Taxes

Income Tax 66K
Effective Tax Rate -0.15%

Stock Price Statistics

The stock price has increased by -92.2% in the last 52 weeks. The beta is 0.67, so Cellectar Biosciences's price volatility has been higher than the market average.

Beta 0.67
52-Week Price Change -92.2%
50-Day Moving Average 0.31
200-Day Moving Average 1.41
Relative Strength Index (RSI) 39.97
Average Volume (20 Days) 1.68M

Income Statement

Revenue n/a
Gross Profit 0
Operating Income -51.78M
Net Income -44.58M
EBITDA -51.78M
EBIT n/a
Earnings Per Share (EPS) -1.22
Full Income Statement

Balance Sheet

The company has 23.29M in cash and 494K in debt, giving a net cash position of 22.79M.

Cash & Cash Equivalents 23.29M
Total Debt 494K
Net Cash 22.79M
Retained Earnings -247.34M
Total Assets 25.47M
Working Capital 14.86M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -47.58M and capital expenditures -104.19K, giving a free cash flow of -47.69M.

Operating Cash Flow -47.58M
Capital Expenditures -104.19K
Free Cash Flow -47.69M
FCF Per Share -1.3
Full Cash Flow Statement

Margins

Gross Margin n/a
Operating Margin n/a
Pretax Margin n/a
Profit Margin n/a
EBITDA Margin n/a
EBIT Margin n/a
FCF Margin n/a

Dividends & Yields

CLRB does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Payout Ratio n/a
Earnings Yield n/a
FCF Yield n/a
Dividend Details

Analyst Forecast

The average price target for CLRB is $28, which is 9555.2% higher than the current price. The consensus rating is "Buy".

Price Target $28
Price Target Difference 9555.2%
Analyst Consensus Buy
Analyst Count 2
Stock Forecasts

Stock Splits

The last stock split was on Jul 22, 2022. It was a backward split with a ratio of 1:10.

Last Split Date Jul 22, 2022
Split Type backward
Split Ratio 1:10

Scores

Altman Z-Score -18.89
Piotroski F-Score 1